Learn more

JANSSEN BIOTECH INC

Overview
  • Total Patents
    2,623
  • GoodIP Patent Rank
    881
  • Filing trend
    ⇩ 30.0%
About

JANSSEN BIOTECH INC has a total of 2,623 patent applications. It decreased the IP activity by 30.0%. Its first patent ever was published in 2001. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are SYNERGEN BIOLOG INC, ALBUMEDIX AS and ALFACELL CORP.

Patent filings per year

Chart showing JANSSEN BIOTECH INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Rezania Alireza 205
#2 Luo Jinquan 187
#3 Wu Sheng-Jiun 175
#4 Teplyakov Alexey 150
#5 Jacobs Steven 147
#6 Sweet Raymond 119
#7 Diem Michael 109
#8 Wheeler John 108
#9 O'Neil Karyn 100
#10 Huang Chichi 98

Latest patents

Publication Filing date Title
WO2021079315A1 Steerable needles
US2021115129A1 Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
WO2021076855A1 Dynamic monosaccharide control processes
WO2021070132A1 Bi-aryl dihydroorotate dehydrogenase inhibitors
WO2021072169A1 Materials and methods for mass spectrometric protein analysis
WO2021064671A1 Methods for producing biotherapeutics with increased stability by sequence optimization
WO2021067191A1 Compositions and methods for an il-17 target engagement assay with small molecule modulators
WO2021067195A1 Compositions and methods for an il-17 target engagement assay with large molecule modulators
WO2021055894A1 Materials and methods for differential characterization of molecular conjugates and conjugation
WO2021059075A1 Anti-ceacam antibodies and uses thereof
US2020392242A1 Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
WO2021038524A1 B-cell maturation complex car t construct and primers
US2020405854A1 Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
WO2021038490A1 Substituted urea dihydroorotate dehydrogenase inhibitors
WO2021038474A1 Tissue anchor and related methods
WO2021041486A1 Chimeric antigen receptor system and uses thereof
US2020397896A1 Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US2021047435A1 Materials and methods for improved single chain variable fragments
WO2021030657A1 Materials and methods for improved single chain variable fragments
US2021047423A1 Therapeutic immune cells with improved function and methods for making the same